Gilead agrees 127-country remdesivir licence with generic makers
14-05-2020
Gilead backs away from antiviral monopoly after criticism
26-03-2020
China approves three Gilead remdesivir patents for COVID-19 treatment
27-02-2020
Sundry Photography / Shutterstock.com
An association representing Indian cancer patients has asked the country’s government to cancel Gilead Sciences’ patents on remdesivir, the experimental antiviral which is hoped can be used to treat coronavirus.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, remdesivir, CPAA, COVID-19, coronavirus, cancer, patent, India, orphan drug, antiviral
